

## HR 6888

### Helping Experts Accelerate Rare Treatments Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 1, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Mar 2, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/6888>

### Sponsor

**Name:** Rep. Tonko, Paul [D-NY-20]

**Party:** Democratic • **State:** NY • **Chamber:** House

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. McKinley, David B. [R-WV-1]	R · WV		Mar 1, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 2, 2022

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
117 HR 7667	Related bill	<b>Jun 9, 2022:</b> Received in the Senate.

### Summary (as of Mar 1, 2022)

#### Helping Experts Accelerate Rare Treatments Act of 2022

This bill requires studies on processes for approving drugs that treat rare diseases and conditions.

The Government Accountability Office (GAO) must contract with an appropriate entity to study the European Union's process for evaluating the safety and efficacy of such drugs, including any flexibilities or mechanisms that are specific to rare diseases or conditions. The GAO must also conduct a study about the Food and Drug Administration's mechanisms for ensuring that patient and physician perspectives are considered when evaluating and approving drugs for rare diseases or conditions.

The GAO must report to Congress the results of these studies.

## Actions Timeline

---

- **Mar 2, 2022:** Referred to the Subcommittee on Health.
- **Mar 1, 2022:** Introduced in House
- **Mar 1, 2022:** Referred to the House Committee on Energy and Commerce.